Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide Prophylaxis for TMA in High-Risk HSCT
NCT03384693Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- May 2018
- Primary completion
- Jul 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of defibrotide in thrombotic microangiopathy (TMA), sponsored by University of California, San Francisco. Started May 2018; status: completed.
02
Drugs
defibrotide
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT03384693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384693.